Updates in Diagnosis and Treatment of Immune Checkpoint Inhibitor Myocarditis
Authors:
- Anthony M. HachemAHAnthony M. Hachem
- Aditya DesaiADAditya Desai
- Noah BeinartNBNoah Beinart
- Keila C. Ostos-MendozaKOKeila C. Ostos-Mendoza
- Ana Sofia Lopez RodriguezARAna Sofia Lopez Rodriguez
- Regina Diaz de Leon DerbyRDRegina Diaz de Leon Derby
- Sara EbrahimiSESara Ebrahimi
- Nicolas L. PalaskasNPNicolas L. Palaskas
- 3 April 2025
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 27 (1) , 1-11
Abstract
Purpose of Review To provide an update on the literature regarding diagnosis and management of immune checkpoint inhibitor myocarditis. Recent Findings The diagnosis of immune checkpoint inhibitor myocarditis has evolved to include more reliance on performing endomyocardial biopsy to clarify the diagnosis in selected cases. Additionally, there is recognition of a spectrum of disease both clinically and on endomyocardial biopsy suggesting that there is a range of severity from mild to fulminant. The treatment of immune checkpoint inhibitor myocarditis is shifting towards increased use of additional immunosuppressive medications as steroid sparing agents. There are increased studies including two randomized controlled trials evaluating abatacept in the treatment of immune checkpoint inhibitor myocarditis. Summary This review summarizes the latest literature regarding diagnosis and management of immune checkpoint inhibitor myocarditis and provides our experience and approach to this rare but potentially fatal condition.Keywords
Funding Information
- Cancer Prevention and Research Institute of Texas (RP200670)
This publication has 59 references indexed in Scilit:
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case reportGynecologic Oncology Reports, 2018
- Myocarditis in Patients Treated With Immune Checkpoint InhibitorsJACC, 2018
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- Survival After Fulminant Myocarditis Induced by Immune-Checkpoint InhibitorsAnnals of Internal Medicine, 2017
- Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapyBritish Journal of Cancer, 2017
- Significance and Value of Endomyocardial Biopsy Based on Our Own ExperienceCirculation Journal, 2017
- Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesEuropean Heart Journal, 2013
- Cardiovascular Magnetic Resonance in Myocarditis: A JACC White PaperJACC, 2009
- Myocarditis. A histopathologic definition and classification.1987